Graduation arc · Diabetes Cure Discovery · Invent Deposition #3361 (2017) → Diabetes Mechanism Analysis — Proof of Function #1

The 2017 seed-line

In 2017, the entry that became Diabetes Mechanism Analysis — Proof of Function #1 was written down as Invent Deposition #3361:

“Immune systemic insulin. insulin medicine to magistrate through the auto immune system immune systemic insulin. insulin medicine to magistrate through the auto immune system insulin main article: insulin therapy type 1 diabetes is typically treated with a combinations of regular and nph insulin, or synthetic insulin analogs. when insulin is used in type 2 diabetes, a long-acting formulation is usually added initially, while continuing oral medications.[29] doses of insulin are then increased to effect.[29] http://en.wikipedia.org/wiki/diabetic.”— © 2017 Christopher Gabriel Brown

What changed between 2017 and the product on the shelf

The 2017 entry was a single-line directive: write down the mechanism, not the brand. Between then and the Proof of Function shipping on this storefront, the work hardened into a 300-row mechanism-analysis database: each row a candidate disease driver, each column a molecular pathway under closed-loop, design-target conditions. Patent-pending. The Proof of Function exposes the database structure, the scoring rubric, and the redaction layer that lets a partner work the IP without exposing the AES-encrypted source archive.

Where it sits in the four-step framework

• Proof of Function — this article’s SKU. A working write-up against representative inputs; available for licensing review at Diabetes Mechanism Analysis — Proof of Function #1.
• Tech Validation — bench data and reproducibility under an evaluation licence.
• Eval Licence — supervised use of the IP package by a partner team.
• Full Acquisition — the patent application, prior-art binder, and prosecution file transfer in full.

→ Open the Proof of Function: Diabetes Mechanism Analysis — Proof of Function #1

Provenance: published 2017 in the Invent Depositions collection (Invent Deposition #3361); part of an intellectual-property portfolio with U.S. patent applications dating to 2012; independently timestamped by the Internet Archive. Patent-pending. Design targets, not warranted performance. First to market — documented public offering, not a determination of patent priority.